Retinal Disease
Phase 3
Completed
- Registration Number
- CTRI/2018/04/012952
- Lead Sponsor
- Giridhar Eye Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
Patients diagnosed with RVO and has not taken any kind of treatment for the same are included in the study with a 6 months follow-up after AntiVEGF therapy
Exclusion Criteria
(a) Intraocular surgery including cataract extraction within 6 months before enrolment (b) Co-existing other retinal diseases (c) Previous laser photocoagulation (d) Intravitreal injection of Triamcinolone acetenoid or antivascular endothelial growth factory (Anti-VEGF) agents (e) prior ocular inflammation.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the ERG changes before and after AntiVEGF pharmacotherapy in patients with retinal vein occlusion.Timepoint: 12 months from the date of enrolment
- Secondary Outcome Measures
Name Time Method Analysis of data for statistical record.Timepoint: 12 months from the date of enrolment